Want to see STVN full AI Analyst Report?
Top Page
Stevanato Group
(NYSE:STVN)
Select Model
Select Model
Rating:67Neutral
Price Target:
$22.50
▲(14.33% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by strong growth and supportive technical momentum, reinforced by constructive guidance and operational highlights from the earnings call. The main constraints are weaker cash-flow conversion/FCF volatility and a less attractive valuation (high P/E with a very low dividend yield).
Positive Factors
High-value solutions mix increasing
A rising share of revenue from high-value solutions reflects a structural shift toward premium, biologics-oriented packaging and delivery products. These programs carry longer qualification cycles, sticky customer relationships and higher margins, supporting more durable revenue streams and greater pricing power over months to years.
Negative Factors
Negative and volatile free cash flow
Persistent free cash flow shortfalls and volatility mean reported earnings have not consistently converted into shareholder cash. That weakens internal funding for capex and dividends, raises reliance on external financing, and limits financial flexibility if investment or market conditions tighten over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High-value solutions mix increasing
A rising share of revenue from high-value solutions reflects a structural shift toward premium, biologics-oriented packaging and delivery products. These programs carry longer qualification cycles, sticky customer relationships and higher margins, supporting more durable revenue streams and greater pricing power over months to years.
Read all positive factors
Stevanato Group (STVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.42B
Dividend Yield0.31%
Average Volume (3M)315.44K
Price to Earnings (P/E)33.7
Beta (1Y)0.84
Revenue Growth15.54%
EPS Growth21.77%
CountryUS
Employees6,010
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.51
Shares Outstanding49,709,717
10 Day Avg. Volume256,276
30 Day Avg. Volume315,443
Financial Highlights & Ratios
PEG Ratio2.50
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$23.00Price Target Upside16.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.6
Revenue Forecast (FY)$1.27B
Stevanato Group Business Overview & Revenue Model
Company Description
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug deliver...
How the Company Makes Money
Stevanato Group makes money primarily by selling products and services used to store, protect, and administer injectable and other parenteral drugs. Key revenue streams include: (1) Drug containment and primary packaging sales: revenue from manufa...
Stevanato Group Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call presented a generally constructive operational and commercial story: top-line growth (8% y/y), strong expansion of high-value solutions (+16%) and significant adjusted EBITDA and margin improvement. The company announced an important commercial milestone (Alina approvals) and ongoing capacity build-outs that support mid- to long-term value capture in biologics. Offsetting these positives were one-time divestiture costs (EUR 12.2m), negative free cash flow in the quarter, elevated net debt, higher taxes, and caution around elongated sales cycles in Engineering. On balance, the highlights — recurring revenue growth, margin expansion, product approvals and clear capacity investments — outweigh the near-term lowlights tied largely to one-time items and measured execution/timing risks.Positive Updates
Revenue Growth
Total revenue grew 8% year-over-year to EUR 302.0 million in Q2 2026 (reported and constant currency). Growth was driven by the Biopharmaceutical & Diagnostic Solutions (BDS) segment, which rose 9% to EUR 266.2 million.
Negative Updates
One-Time Divestiture Costs and Revenue Removal
Completed sale of U.S. subsidiary Balda C. Brewer generated one-time transaction expenses of EUR 12.2 million in Q2 2026. The divested subsidiary had been expected to generate approximately EUR 30 million of revenue in fiscal 2026; the company factored a revenue reduction of ~EUR 15 million into updated guidance.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth
Total revenue grew 8% year-over-year to EUR 302.0 million in Q2 2026 (reported and constant currency). Growth was driven by the Biopharmaceutical & Diagnostic Solutions (BDS) segment, which rose 9% to EUR 266.2 million.
Read all positive updates
Company Guidance
Management updated full‑year 2026 guidance to revenue of €1.260–€1.280 billion (reflecting ~€15m less from the Balda C. Brewer divestiture), adjusted EBITDA of €335–€345.2m (center point implying an adjusted EBITDA margin of ~26.8%, about +170 bps year‑over‑year), and adjusted diluted EPS of €0.60–€0.62; high‑value solutions are expected to make up 47–48% of revenue. Segment assumptions: BDS is expected to grow reported high single digits (organic growth remains double‑digit after currency and divestiture adjustments) while Engineering is expected to decline mid‑single digits to low‑double digits. Cash‑flow and tax guidance: free cash flow is forecast between breakeven and +€20m and an adjusted tax rate of ~28.2% (partly offset by lower‑than‑anticipated depreciation, amortization and financial expenses); the divestiture is expected to be accretive to full‑year margins.Stevanato Group Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
74
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.20B | 1.14B | 1.10B | 1.09B | 983.68M | 843.92M |
| Gross Profit | 348.16M | 330.33M | 302.32M | 339.89M | 319.80M | 265.40M |
| EBITDA | 294.22M | 288.54M | 247.80M | 272.35M | 256.40M | 226.93M |
| Net Income | 140.95M | 134.28M | 117.78M | 145.63M | 142.85M | 134.32M |
Balance Sheet | ||||||
| Total Assets | 2.58B | 2.54B | 2.33B | 2.07B | 1.66B | 1.42B |
| Cash, Cash Equivalents and Short-Term Investments | 112.73M | 132.74M | 98.27M | 70.35M | 256.65M | 438.21M |
| Total Debt | 448.52M | 470.70M | 428.97M | 396.59M | 218.37M | 244.29M |
| Total Liabilities | 1.05B | 1.06B | 924.43M | 938.93M | 663.79M | 577.18M |
| Stockholders Equity | 1.53B | 1.49B | 1.40B | 1.13B | 996.13M | 842.07M |
Cash Flow | ||||||
| Free Cash Flow | -7.11M | 21.44M | -157.79M | -336.72M | -139.81M | 20.16M |
| Operating Cash Flow | 260.08M | 274.79M | 155.78M | 105.21M | 103.31M | 133.34M |
| Investing Cash Flow | -271.01M | -262.15M | -310.21M | -421.22M | -242.95M | -96.43M |
| Financing Cash Flow | 32.70M | 21.19M | 183.22M | 158.03M | -44.54M | 254.85M |
Stevanato Group Technical Analysis
Positive
19.68
Price Trends
18.77
Positive
17.32
Positive
18.60
Positive
Market Momentum
0.43
Positive
57.69
Neutral
61.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STVN, the sentiment is Positive. The current price of 19.68 is below the 20-day moving average (MA) of 19.79, above the 50-day MA of 18.77, and above the 200-day MA of 18.60, indicating a bullish trend. The MACD of 0.43 indicates Positive momentum. The RSI at 57.69 is Neutral, neither overbought nor oversold. The STOCH value of 61.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STVN.
Stevanato Group Risk Analysis
Stevanato Group disclosed 64 risk factors in its most recent earnings report. Stevanato Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stevanato Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $5.08B | 34.70 | 9.07% | ― | 10.51% | 20.67% | |
75 Outperform | $2.32B | 36.71 | 16.42% | 0.94% | 13.27% | 36.99% | |
69 Neutral | $8.55B | 23.92 | 13.52% | 1.43% | 8.93% | -5.14% | |
69 Neutral | $7.96B | 190.55 | 1.98% | ― | 16.49% | ― | |
67 Neutral | $5.42B | 33.75 | 9.63% | 0.32% | 15.54% | 21.77% | |
59 Neutral | $6.05B | -6.00 | -31.83% | 1.03% | -6.61% | -812.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
STVN
Stevanato Group
20.27
-1.50
-6.89%
ATR
AptarGroup
135.42
-2.36
-1.72%
LMAT
Lemaitre Vascular
81.45
-10.33
-11.25%
MMSI
Merit Medical Systems
89.04
5.00
5.95%
RGEN
Repligen
163.90
52.02
46.50%
TFX
Teleflex
134.98
20.34
17.75%
Stevanato Group Corporate Events
Stevanato Group Details Mid-2026 Performance and Risk Landscape in Unaudited Interim Report
Aug 4, 2026
Stevanato Group has filed an unaudited interim report for the three and six months ended June 30, 2026, providing condensed consolidated financial statements and a management discussion of its financial condition and results of operations. The fil...
Stevanato Group Posts 8% Q2 Revenue Growth and Sells U.S. Subsidiary Balda C. Brewer
Aug 4, 2026
Stevanato Group reported that in the second quarter of 2026, ended June 30, revenue rose 8% year over year to €302.0 million, with high-value solutions contributing 45% of sales and adjusted EBITDA margin improving to 26.0%. Net profit reach...
Stevanato Group Files Form 6-K Detailing Q2 2026 Investor Presentation
Aug 4, 2026
On August 4, 2026, Stevanato Group filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing a presentation used for its Q2 2026 financial results investor conference call held the same day. The filing confirms the company̵...
Stevanato Group Shareholders Approve 2025 Accounts, Dividend and Governance Changes
Jun 5, 2026
Stevanato Group held its Ordinary and Extraordinary Shareholders’ Meeting virtually on May 26, 2026, where investors approved the 2025 financial statements and a dividend of €0.054 per outstanding Class A and ordinary share, excluding ...
Stevanato Group Posts Strong Q1 2026 Growth and Accelerates Cartridge Capacity Expansion
May 15, 2026
Stevanato Group reported that its first-quarter 2026 financial results, discussed on a May 7 earnings call, showed 10% constant-currency revenue growth, driven mainly by the Biopharmaceutical and Diagnostic Solutions segment and strong demand for ...
Stevanato Group Calls May 26, 2026 Teleconference Shareholders’ Meeting to Approve 2025 Results and Board Slate
May 11, 2026
On May 11, 2026, Stevanato Group filed a Form 6-K in the U.S. disclosing materials tied to its upcoming corporate governance cycle, including the convening notice and explanatory report for its shareholders’ meeting, committee reports, a sus...
Stevanato Group Files Form 6-K Detailing Q1 2026 Results Presentation
May 7, 2026
On May 7, 2026, Stevanato Group S.p.A. furnished a Form 6-K to the U.S. Securities and Exchange Commission as a foreign private issuer, covering its activities for May 2026. The filing lists an investor presentation related to the company’s ...
Stevanato Group Files First-Quarter 2026 Interim Report Highlighting Risk Landscape
May 7, 2026
Stevanato Group has filed an unaudited interim report on Form 6-K for the three months ended March 31, 2026, providing condensed consolidated financial statements and management’s discussion of its financial condition and results. The filing...
Stevanato Group Posts Q1 2026 Revenue Growth and Reaffirms Full-Year Guidance
May 7, 2026
In the first quarter of 2026, Stevanato Group reported revenue of €273.6 million, up 7% year-over-year, or 10% at constant currency, with high-value solutions rising 17% and reaching 47% of total sales. The Biopharmaceutical and Diagnostic S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.